There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities. We aim to systematically review the primary literature and to provide recommendations with regard to the use of metformin in psychiatric populations prescribed second-generation antipsychotics. The authors undertook a literature search of Medline, EMBASE, and PsycINFO using the search terms; antipsychotic OR atypical antipsychotic AND weight AND metformin. Narrative review was undertaken without additional statistical analysis. The search provided 198 results from which 10 original research papers were identified: six randomized controlled trials and one open-label study for adults and two randomized controlled trials and one open-label study for children and adolescents. Four meta-analyses were also identified. We concluded that if weight gain occurs after second-generation antipsychotic initiation, despite lifestyle intervention, metformin should be considered. Further studies with adequate statistical power are required to determine the efficacy of metformin in those with chronic psychotic illness.
Introduction
Increasing use of second-generation antipsychotics (SGA) in major psychiatric illness has shifted clinical concern from extrapyramidal side effects to other health consequences, namely weight-gain and adverse cardiometabolic risk. SGA medications, particularly clozapine and olanzapine and to a lesser extent quetiapine and risperidone, are associated with weight gain, disrupted glucose metabolism, and abnormal lipid profile (Stahl et al., 2009) ; changes that occur early in the course of the treatment (Tarricone et al., 2010) . The 20% discrepancy in life expectancy in people who suffer psychotic illness compared with the general population is overwhelmingly due to higher rates of cardiovascular diseases (Hennekens et al., 2005) . Furthermore, risk may be compounded by genetic predisposition, illness-associated sedentary lifestyle (Pramyothin and Khaodhiar, 2010) , and high rates of tobacco smoking (De Leon and Diaz, 2005) .
The underlying mechanism of metabolic dysregulation is poorly understood. Although causation is presumably complex and multifactorial, weight gain after the initiation of SGA medication appears to be the factor promoting the majority of cardiovascular risk (Foley and Morley, 2011) . There is evidence that the antipsychotic binding affinity for specific receptor subtypes, primarily H 1 and 5-HT 2C (Kroeze et al., 2003; De Luca et al., 2007) , correlates with degree of weight gain. 5-HT 2C receptor antagonism may downregulate leptin-mediated appetite suppression and satiety signalling from the gut, whereas H 1 antagonism is known to cause mild sedation that may promote physical inactivity (Reynolds and Kirk, 2010) .
The multifactorial nature of SGA-induced weight gain makes development of pharmaceuticals to counterpoise adverse cardiometabolic parameters problematic. Potential agents are limited to nonspecific pharmaceuticals known to have weight loss effects in nonpsychiatric populations. Although there is a paucity of comparative literature, a recent meta-analysis has shown metformin to have the greatest impact on SGA-induced weight gain (Maayan et al., 2010) .
Metformin is an oral antihyperglycaemic agent used primarily for the treatment of type 2 diabetes mellitus. Metformin is recognized as a weight neutral agent in patients suffering from type 2 diabetes and may also have weight-attenuating properties in obese adolescents (Rezvanian et al., 2010) and patients suffering from polycystic ovarian syndrome (Katsiki et al., 2009) . Its mechanism of action involves suppression of hepatic gluconeogenesis, stimulation of glucose uptake by skeletal muscle (Wiernsperger and Bailey, 1999) , and augmentation of insulin activity by strengthening adenosine monophosphate kinase signalling (Kim et al., 2011) .
This study aims to undertake a systematic review to identify all available clinical studies, in both pediatric and adult populations, in which metformin has been investigated as a therapy for the prevention or attenuation of weight gain or improvement of metabolic parameters in psychiatric populations treated with SGA medications.
Methods
Online literature search of Medline 1966 to April 2011 , EMBASE 1988 to April 2011 , and PsycINFO 1967 to April 2011 was undertaken using the search terms; antipsychotic OR atypical antipsychotic AND weight AND metformin, which yielded 198 results. The search was limited to English language publications. The title and abstract of 79 original research and meta-analytical articles were reviewed resulting in the identification of 10 suitable original research papers: six randomized controlled trials (RCTs) and one open-label study conducted in adults, and two RCTs and one open-label study conducted in children and adolescents. One open-label study (Baptista et al., 2001) was excluded because of a small sample size (five patients). One RCT was excluded due to lack of information on weight-associated outcomes (Baptista et al., 2007b) and another (Fernandez et al., 2010) because the study shared a cohort previously reported in another RCT (Carrizo et al., 2009) . Four meta-analyses (Bjorkhem-Bergman et al., 2010; Ehret et al., 2010; Maayan et al., 2010; Praharaj et al., 2011) were identified.
Ten studies and four meta-analyses included in this review are summarized in Tables 1 and 2 . Statistical data from the source material are reported, no additional statistical analysis was performed.
Results
In all but one study, metformin was the only active pharmaceutical intervention. One study (Baptista et al., 2008) investigated the efficacy of metformin combined with sibutramine (a medication since withdrawn), compared with controls receiving metformin with placebo. Wu et al. (2008b) was the only study group to compare metformin, lifestyle intervention, and a combination of both to placebo. Two studies (Arman et al., 2008; Wu et al., 2008a) investigated treatment-naïve first-episode psychosis (FEP), whereas the remainder of studies investigated patients receiving SGAs for between 3 months and 30 years. Dosing of metformin varied between 500 and 3400 mg daily in divided doses. All but one RCT (Wu et al., 2008b) did not control for lifestyle or dietary interventions; two of the RCTs (Arman et al., 2008; Baptista et al., 2008) did not specify any lifestyle or dietary interventions. The remaining RCTs provided varied dietary and exercise advice to both metformin and placebo groups.
The primary outcomes in various studies included:
(1) Body weight (BW), body mass index (BMI), fasting blood sugar levels (BSL), insulin resistance, and lipid profile (Baptista et al., 2006 (Baptista et al., , 2007a (Baptista et al., , 2008 Chen et al., 2008; Carrizo et al., 2009 ). (2) BW, BMI, and BSL (Klein et al., 2006; Arman et al., 2008; Wu et al., 2008a Wu et al., , 2008b . (3) BW and BMI (Morrison et al., 2002) .
Schizophrenia was the primary diagnosis in the majority of studies with a minority diagnosed with bipolar, schizoaffective, and pediatric behavioural disorders.
Studies conducted in adult populations with established illness (Table 1 ) Carrizo et al. (2009) assessed metformin in 61 clozapinetreated patients, with a mean duration of treatment of 86.5 months and a mean age of 38.9 years. Metformin showed a statistically significant effect on BW and BMI compared with placebo. Metformin had no significant effect on fasting BSL compared with placebo; however, there was a slight reduction in fasting insulin and HbA1c in the metformin group compared with placebo. Highdensity lipoprotein increased in the metformin group compared with placebo, with no significant changes in other lipid parameters. Baptista et al. (2007a) assessed the utility of metformin in 80 patients with schizophrenia with a mean duration of treatment 6.7 months and mean age of 44.5 years. This study found no differences in weight, glucose, or lipid outcomes between the metformin and placebo groups.
A subsequent study conducted by Baptista et al. (2008) compared metformin with coadministered sibutramine to metformin with placebo. This study found significant decrease in waist circumference, fasting BSL, fasting insulin, low-density lipoprotein, and total cholesterol in the metformin and placebo groups at study conclusion compared with the baseline. However, this study lacked a double-placebo group and therefore cannot be considered a true RCT of metformin alone.
A third study conducted by Baptista et al. (2006) in 40 patients with schizophrenia with a mean age of 47.7 years, investigated the efficacy of metformin in patients newly commenced on olanzapine. This is the only study investigating metformin for prevention of weight gain in chronic populations, newly commenced on SGA medication. Although this RCT showed no significant differences between placebo and metformin groups, there was a reduction in BSL, serum insulin, triglycerides, and insulin independent of weight loss in the metformin group alone. Wu et al. (2008b) performed the only RCT, which provided a group that controlled for lifestyle intervention. Patients (n = 128) with a diagnosis of first-episode psychosis with a mean age of 26.3 years who had gained greater than 10% of BW within 12 months after commencing treatment with clozapine, olanzapine, risperidone, or sulpiride were randomized to receive either Klein et al. (2006) investigated the utility of metformin in 39 pediatric patients with a mean age of 13.1 years who had gained more than 10% of their pretreatment weight within 12 months of commencing either olanzapine, risperidone, or quetiapine. As the study was conducted in growing children, age-corrected changes in the standard deviation of weight and BMI were used. Metformin was shown to have a significant impact on reducing BW, BMI, and waist circumference compared with placebo. Morrison et al. (2002) performed an open-label study in 19 patients with a mean age of 14 years who had gained more than 10% of their pretreatment weight after commencing treatment with olanzapine, risperidone, quetiapine, or valproate. Metformin was shown to have a significant impact on reducing BW and BMI compared with placebo.
Studies conducted in first-episode psychosis or drug-naïve populations Arman et al. (2008) conducted a RCT to determine the impact of metformin on 49 pediatric patients with FEP recently commenced on risperidone. Patients had a mean age of 11.3 years. There were no significant differences in weight or glucose related parameters between metformin and placebo groups. Wu et al. (2008a) conducted a RCT of 40 FEP to determine the impact of metformin in patients newly commenced on olanzapine. Patients had a mean age of 25 years and normal BMI (range: 18.5-23.9) at study beginning. Although BW and BMI increased in both groups, there was significant attenuation of these parameters in the metformin group compared with placebo. Those patients receiving metformin had a significant reduction in serum insulin and insulin resistance index compared with placebo.
Meta-analysis (Table 3) Two meta-analyses (Ehret et al., 2010; Maayan et al., 2010) that included studies examining various SGA medications showed a significant reduction in BW, BMI, and waist circumference in the metformin group compared with placebo. There was a significant reduction in serum insulin and triglycerides in one meta-analysis (Maayan et al., 2010) and a reduction in homeostatic method of assessment -insulin resistance in the other (Ehret et al., 2010) . Heterogeneity in outcome was very high across all analyses.
One meta-analysis (Praharaj et al., 2011) included studies in which olanzapine was the only treatment. This study showed a greater absolute BW reduction than reported in other meta-analyses. Heterogeneity was insignificant.
One meta-analysis (Bjorkhem-Bergman et al., 2010) reported weight reduction as a percentage of pretreatment weight. Proportional reduction was significant in the metformin group compared with placebo, heterogeneity was very high. On sub group analysis weight loss was greater in those patients who had gained greater than 10% of their pretreatment weight after commencing SGA therapy. 
Discussion
The current literature suggests that metformin is the most suitable agent for the prevention and treatment of weight gain associated with SGA medication (Maayan et al., 2010) . Four RCTs (Klein et al., 2006; Wu et al., 2008a Wu et al., , 2008b Carrizo et al., 2009) indicate that metformin has a statistically significant impact on BW and BMI, whereas meta-analysis suggests that metformin may induce weight loss of up to 3 kg (Ehret et al., 2010) and reduce BW by approximately 5% in adult and pediatric patients treated with a variety of SGA medications (Bjorkhem-Bergman et al., 2010) . Furthermore, weight loss may be enhanced in patients at an increased risk of weight gain, namely those exposed to olanzapine and those who gain greater than 10 kg after first SGA exposure (Bjorkhem-Bergman et al., 2010) .
Although encouraging, various limitations inherent in the current literature merit discussion. First, there is a paucity of adequately powered studies available, with only four of nine RCTs able to draw statistically significant conclusions. The majority of nonsignificant studies were conducted in relatively older cohorts with longer disease and treatment duration, which may confound comparisons with the younger cohorts of the significant studies. This observation is mirrored by the substantial heterogeneity of meta-analyzed effect size (see Table 3 ).
Second, lifestyle intervention is only controlled for in one RCT (Wu et al., 2008b) , whose results indicate that lifestyle intervention combined with metformin is superior to either intervention alone. A recent meta-analysis found structured lifestyle intervention to attenuate SGAinduced weight gain resulted in pooled weight loss of 2.56 kg (Alvarez-Jimenez et al., 2008) . Considering most RCTs provided uncontrolled lifestyle advice to both metformin and placebo groups, it is possible that this is accounting for a large proportion of the effect size. Repetition of the methodology used by Wu et al. (2008b) in drug-naïve populations is desirable.
Third, most primary research has been conducted in Asian and Hispanic populations, with two (Wu et al., 2008a (Wu et al., , 2008b of the significant studies conducted in the former group. Normative BMI varies between ethnic groups, and recommended BMI and waist circumference reference ranges for Asians are less than for other populations (World Health Organisation, 2004) . Furthermore, waist circumference is superior to BMI in predicting the risk of diabetes (Klein et al., 2007) , whereas excess waist circumference constitutes a cardiovascular risk factor in those who are neither overweight nor obese on BMI measurement (Meisinger et al., 2006) . Wu et al. (2008b) was the only study to show between-group statistically significant reductions in waist circumference with metformin.
Although none of the studies reviewed here directly report on the side effects of metformin or its potential interaction with atypical antipsychotic medication, metformin has a safety profile established through long-term use. Gastrointestinal symptoms (nausea, bloating, and diarrhoea) are the most commonly reported adverse drug reactions, reported in up to 30% of patients; however, these symptoms can largely be avoided by gradual dose titration and appropriate food intake (Scheen, 2005) . Lactic acidosis is known to occur at a rate of approximately 3 in 100 000 patients usually as a result of inappropriate prescribing in patients with impaired renal function (Strack, 2008) . Importantly metformin is not metabolised by hepatic P 450 enzymes and is not reported to have any significant drug-drug interactions, or specific interactions with antipsychotic medications (Howlett and Bailey, 1999) . 
Eight RCTs (Baptista et al., 2006 (Baptista et al., , 2007a (Baptista et al., , 2008 Klein et al., 2006; Arman et al., 2008; Wu et al., 2008a Wu et al., , 2008b Carrizo et al., 2009) Meta-analysis of all potential pharmacotherpaies for weight loss in patients receiving SGA Pediatric and adult studies pooled Any SGA 2.94 kg reduction in BW (I 2 = 91%) 2.26 cm reduction in WC 7.22 mIU/ml reduction in insulin 28.07 mg/dl reduction in triglycerides Changes in HDL, LDL, HOMA-IR, and fasting BSL not significant Ehret et al. (2010) Six RCTs (Baptista et al., 2006 (Baptista et al., , 2007a Klein et al., 2006; Arman et al., 2008; Wu et al., 2008a Wu et al., , 2008b Meta-analysis of metformin's impact on BW, BMI, WC, and HOMA-IR compared with placebo Pediatric and adult studies pooled Any SGA 3.16 kg reduction in BW (I 2 = 84%) 1.21 reduction in BMI 1.99 cm reduction in WC 1.71 reduction in HOMA-IR Praharaj et al.
Four RCTs (Baptista et al., 2006 (Baptista et al., , 2007a (Baptista et al., , 2007b Wu et al., 2008a Wu et al., , 2008b Meta-analysis of metformin for reduction of weight gain in olanzapine-treated patients BW, BMI, and WC primary outcome 5.02 kg reduction in BW (I 2 = 0%) 1.42 reduction in BMI (I 2 = 85%) 1.82 cm reduction in WC (I 2 = 0%) Bjorkhem-Bergman et al. (2010) Five adult RCTs (Baptista et al., 2006 (Baptista et al., , 2007a Wu et al., 2008a Wu et al., , 2008b Carrizo et al., 2009) Current recommendations regarding metformin are conflicting. One author has proposed a guideline for the use of metformin in patients with cumulative risk factors (Hasnain et al., 2010) , whereas others cite poor statistical power of the primary evidence and inadequate weight loss as grounds to advise against routine use of metformin (Desilets et al., 2008; Bushe et al., 2009 ). Although we agree that the utility of metformin has not been elucidated in older populations with longer treatment duration, the significant efficacy of metformin in younger populations with shorter illness and treatment duration makes use of metformin in this group advantageous. The augmented efficacy of metformin in those patients who have gained greater than 10% of their BW within 1 year of commencing SGA treatment indicates this group may also benefit from the use of metformin.
Weight gain associated with SGA medications is most rapid during the first 12 weeks of treatment and universal in FEP regardless of antipsychotic used (Tarricone et al., 2010) . Younger patients may also be at increased risk of diabetes and there is evidence that risk diminishes with increasing age (Hammerman et al., 2008) . Utilisation of metformin in the early stages of SGA treatment is proven to substantially mitigate weight gain at a time of major cardiometabolic vulnerability. Psychosis typically manifests in late adolescence or early adulthood (Kirkbride et al., 2006) and weight gain at this stage of treatment contributes to increased cardiovascular risk regardless of future weight loss (Must et al., 1992) . For this reason, mitigation of weight gain in early stages of treatment is potentially more clinically advantageous than net weight loss in chronic patients who have undergone indeterminate weight gain.
The desirability of preventing avoidable weight gain is not simply about mitigating risk of premature cardiovascular morbidity and mortality. The impact of rapid weight gain for any young person undergoing the social and psychological transition from adolescence to adulthood is considerable and is also the time at which psychosis typically manifests. The dual stigma and discrimination (Hatzenbuehler et al., 2009 ) encountered by individuals suffering both psychotic illness and obesity contributes to psychological distress (Simon et al., 2006) , poor selfesteem (De Hert et al., 2006) , and may impact medication compliance, risking relapse. Avoidance of this is both advantageous to the individual and reduces health costs associated with relapse (Knapp et al., 2004) . Weight gain compromises quality of life, general health, and decreases physical and social functioning (Kolotkin et al., 2006) , imposing role limitations that have been shown to be a more important issue to people living with psychosis than the psychiatric condition itself (Dixon et al., 2001) .
We have developed a clinical decision tool incorporating the current evidence to detect and assertively intervene in antipsychotic induced weight gain, with the aim of actively preserving cardiometabolic health (Curtis et al., 2011) ; http://www.ceti.nsw.gov.au/www/472/1001127/display article/1007767.html). It is our recommendation that all patients commencing atypical antipsychotic medication be monitored for metabolic side effects, including monitoring of weight, waist circumference, BMI, blood pressure and fasting blood glucose or HbA1c, and lipid profile. Structured lifestyle and nutritional advice should be provided for all patients presenting with FEP and chronic mental illness. In those who gain greater than ten percent of their BW despite lifestyle intervention, there is evidence that metformin is an effective pharmacological adjunct to lifestyle. Metformin efficacy in the at-risk is supported by evidence showing weight reduction in obese, euglycemic adolescents (Casteels et al., 2010; Rezvanian et al., 2010) . Not including metformin as part of the clinical armamentarium risks missing an important opportunity to positively influence the health trajectory of patients suffering psychotic illness.
Conclusion
Metformin is efficacious in preventing weight gain in younger population groups and those who gain substantial weight within 1 year of commencing SGA treatment. The primary literature has a variety of limitations, nevertheless the literature uniformly demonstrates that metformin with lifestyle intervention is effective in these patient groups.
